1. Home
  2. EVO vs ETG Comparison

EVO vs ETG Comparison

Compare EVO & ETG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVO
  • ETG
  • Stock Information
  • Founded
  • EVO 1993
  • ETG 2003
  • Country
  • EVO Germany
  • ETG United States
  • Employees
  • EVO N/A
  • ETG N/A
  • Industry
  • EVO Biotechnology: Pharmaceutical Preparations
  • ETG Investment Managers
  • Sector
  • EVO Health Care
  • ETG Finance
  • Exchange
  • EVO Nasdaq
  • ETG Nasdaq
  • Market Cap
  • EVO 1.6B
  • ETG 1.5B
  • IPO Year
  • EVO 2021
  • ETG N/A
  • Fundamental
  • Price
  • EVO $4.44
  • ETG $18.98
  • Analyst Decision
  • EVO Buy
  • ETG
  • Analyst Count
  • EVO 2
  • ETG 0
  • Target Price
  • EVO $5.90
  • ETG N/A
  • AVG Volume (30 Days)
  • EVO 46.1K
  • ETG 132.1K
  • Earning Date
  • EVO 11-06-2024
  • ETG 01-01-0001
  • Dividend Yield
  • EVO N/A
  • ETG 6.64%
  • EPS Growth
  • EVO N/A
  • ETG N/A
  • EPS
  • EVO N/A
  • ETG N/A
  • Revenue
  • EVO $866,665,179.00
  • ETG N/A
  • Revenue This Year
  • EVO $3.84
  • ETG N/A
  • Revenue Next Year
  • EVO $10.94
  • ETG N/A
  • P/E Ratio
  • EVO N/A
  • ETG N/A
  • Revenue Growth
  • EVO N/A
  • ETG N/A
  • 52 Week Low
  • EVO $2.85
  • ETG $14.08
  • 52 Week High
  • EVO $7.98
  • ETG $18.34
  • Technical
  • Relative Strength Index (RSI)
  • EVO 49.82
  • ETG 51.67
  • Support Level
  • EVO $4.40
  • ETG $18.90
  • Resistance Level
  • EVO $4.49
  • ETG $19.23
  • Average True Range (ATR)
  • EVO 0.10
  • ETG 0.17
  • MACD
  • EVO -0.00
  • ETG 0.00
  • Stochastic Oscillator
  • EVO 38.46
  • ETG 65.75

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About ETG Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.

Share on Social Networks: